However, although combination therapy of osimertinib and trametinib (MEK inhibitor) successfully inhibited the proliferation of NSCLC cell lines harboring BRAF fusions in a synergistic manner, a patient with AGK-BRAF fusion had difficulty tolerating such a combination regimen and ultimately discontinued treatment, owing to overlapped toxicity of inhibitors of EGFR and MAPK pathway [143, 144]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.